XML 64 R51.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Acquisitions (Details) - Villaris Therapeutics, Inc. - USD ($) $ in Millions | 12 Months Ended |
--- | --- | ---
Dec. 31, 2023 | Dec. 31, 2022 | Nov. 17, 2022
Asset Acquisition [Line Items] |  |  |
Outstanding shares acquired |  |  | 100.00%
Upfront payment |  | $ 70.3 |
Asset acquisition payment for contingent consideration liability | $ 20.0 |  |
Asset Acquisition, Milestone One |  |  |
Asset Acquisition [Line Items] |  |  |
Contingent consideration | 290.0 |  |
Asset Acquisition, Milestone Two |  |  |
Asset Acquisition [Line Items] |  |  |
Contingent consideration | $ 1,050.0 |  |

X
- Definition Asset Acquisition Payment For Contingent Consideration Liability + References No definition available. + Details
Name: | incy_AssetAcquisitionPaymentForContingentConsiderationLiability
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, Percentage of Shares Acquired + References No definition available. + Details
Name: | incy_AssetAcquisitionPercentageOfSharesAcquired
Namespace Prefix: | incy_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liability recognized from contingent consideration in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=incy_VillarisTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AssetAcquisitionMilestonesAxis=incy_AssetAcquisitionMilestoneOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AssetAcquisitionMilestonesAxis=incy_AssetAcquisitionMilestoneTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |